110 related articles for article (PubMed ID: 26366867)
1. Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme.
Lim SM; Choi J; Chang JH; Sohn J; Jacobson K; Policht F; Schulz J; Cho BC; Kim SH
PLoS One; 2015; 10(9):e0137678. PubMed ID: 26366867
[TBL] [Abstract][Full Text] [Related]
2. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
3. Association between glioblastoma cell-derived vessels and poor prognosis of the patients.
Mei X; Chen YS; Zhang QP; Chen FR; Xi SY; Long YK; Zhang J; Cai HP; Ke C; Wang J; Chen ZP
Cancer Commun (Lond); 2020 May; 40(5):211-221. PubMed ID: 32359215
[TBL] [Abstract][Full Text] [Related]
4. Identification of ROS1 rearrangement in gastric adenocarcinoma.
Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
[TBL] [Abstract][Full Text] [Related]
5. Rare Incidence of
Lim SM; Yoo JE; Lim KH; Meng Tai DW; Cho BC; Park YN
Cancer Res Treat; 2017 Jan; 49(1):185-192. PubMed ID: 27121721
[TBL] [Abstract][Full Text] [Related]
6. Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma.
Kraus TF; Kolck G; Greiner A; Schierl K; Guibourt V; Kretzschmar HA
Tumour Biol; 2015 Nov; 36(11):8439-46. PubMed ID: 26022161
[TBL] [Abstract][Full Text] [Related]
7. A simple quantitative diagnostic alternative for MGMT DNA-methylation testing on RCL2 fixed paraffin embedded tumors using restriction coupled qPCR.
Pulverer W; Hofner M; Preusser M; Dirnberger E; Hainfellner JA; Weinhaeusel A
Clin Neuropathol; 2014; 33(1):50-60. PubMed ID: 23993306
[TBL] [Abstract][Full Text] [Related]
8. A practical review of prognostic correlations of molecular biomarkers in glioblastoma.
Karsy M; Neil JA; Guan J; Mahan MA; Colman H; Jensen RL
Neurosurg Focus; 2015 Mar; 38(3):E4. PubMed ID: 25727226
[TBL] [Abstract][Full Text] [Related]
9. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma.
Villani V; Casini B; Pace A; Prosperini L; Carapella CM; Vidiri A; Fabi A; Carosi M
Dis Markers; 2015; 2015():604719. PubMed ID: 26347581
[TBL] [Abstract][Full Text] [Related]
11. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
[TBL] [Abstract][Full Text] [Related]
12. The contrasting epigenetic role of RUNX3 when compared with that of MGMT and TIMP3 in glioblastoma multiforme clinical outcomes.
Saraiva-Esperón U; Ruibal A; Herranz M
J Neurol Sci; 2014 Dec; 347(1-2):325-31. PubMed ID: 25467143
[TBL] [Abstract][Full Text] [Related]
13. Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation.
Yoshikawa A; Nakada M; Watanabe T; Hayashi Y; Sabit H; Kato Y; Suzuki S; Ooi A; Sato H; Hamada J
Brain Tumor Pathol; 2013 Jul; 30(3):175-9. PubMed ID: 23053494
[TBL] [Abstract][Full Text] [Related]
14. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
[TBL] [Abstract][Full Text] [Related]
15. Frequent aerogenous spread with decreased E-cadherin expression of ROS1-rearranged lung cancer predicts poor disease-free survival.
Jin Y; Sun PL; Park SY; Kim H; Park E; Kim G; Cho S; Kim K; Lee CT; Chung JH
Lung Cancer; 2015 Sep; 89(3):343-9. PubMed ID: 26149475
[TBL] [Abstract][Full Text] [Related]
16. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J
Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.
Grasbon-Frodl EM; Kreth FW; Ruiter M; Schnell O; Bise K; Felsberg J; Reifenberger G; Tonn JC; Kretzschmar HA
Int J Cancer; 2007 Dec; 121(11):2458-64. PubMed ID: 17691113
[TBL] [Abstract][Full Text] [Related]
18. Confounding factors in diagnostics of MGMT promoter methylation status in glioblastomas in stereotactic biopsies.
Weise LM; Harter PN; Eibach S; Braczynski AK; Dunst M; Rieger J; Bähr O; Hattingen E; Steinbach JP; Plate KH; Seifert V; Mittelbronn M
Stereotact Funct Neurosurg; 2014; 92(3):129-39. PubMed ID: 24776650
[TBL] [Abstract][Full Text] [Related]
19. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.
Ellingson BM; Cloughesy TF; Pope WB; Zaw TM; Phillips H; Lalezari S; Nghiemphu PL; Ibrahim H; Naeini KM; Harris RJ; Lai A
Neuroimage; 2012 Jan; 59(2):908-16. PubMed ID: 22001163
[TBL] [Abstract][Full Text] [Related]
20. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]